Suppr超能文献

在左甲状腺素停药后进行放射性碘消融治疗前,刺激甲状腺球蛋白值高于5.6 ng/ml与Tg-ab阴性的分化型甲状腺癌患者2.38倍的复发风险相关。

Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.

作者信息

Mousa U, Yikilmaz A S, Nar A

机构信息

Department of Endocrinology and Metabolism, Baskent University School of Medicine, 5. Sokak No 48 Bahcelievler-Cankaya, Ankara, Turkey.

Department of Internal Medicine, Baskent University School of Medicine, Ankara, Turkey.

出版信息

Clin Transl Oncol. 2017 Aug;19(8):1028-1034. doi: 10.1007/s12094-017-1640-3. Epub 2017 Mar 3.

Abstract

BACKGROUND

Serum thyroglobulin (Tg) is the key parameter used in the follow-up of subjects with differentiated thyroid cancer (DTC). Current guidelines advise its measurement to take place when Thyrotropin (TSH) levels are >30 µU/ml (stimulated Tg) and when TSH < 0.1 µU/ml (suppressed Tg). Although stimulated Tg levels <1 ng/ml have been shown to display excellent prognosis, relapses may occur despite low Tg levels. Recently, very low cut-off levels of stimulated Tg have been proposed for determining the recurrence risk in these subjects. In this study, we aimed to assess the association between ablative stimulated Tg obtained before radioactive iodine ablation therapy (RAI) (ASTg) and late stimulated Tg obtained 6-12 months after primary therapy (LSTg) in a group of subjects with DTC. We also aimed to establish a cut-off level of Tg for recurrence.

METHODS

We retrospectively analyzed 393 subjects with low or intermediate risk DTC diagnosed at our institution between January 2000 and December 2010 with a mean follow-up period of 64.4 months (range 14-192 months). All stimulated Tg levels were performed following levothyroxine withdrawal in this study.

RESULTS

Histopathological analysis indicated papillary carcinoma in 362 (92.1%) subjects and follicular carcinoma in 31 (7.9%) subjects. Three hundred and twenty-four (82.4%) of our cases were females, and 69 (17.6%) were males. Recurrence occurred in 82 (20.9%) of the subjects. Relapse was significantly more frequently observed in subjects with ASTg ≥ 2 ng/ml; and LSTg ≥ 2 ng/ml. (p = 0.004 and p < 0.001, respectively). In subjects negative for thyroglobulin antibodies (Tg-ab), an ASTg value ≥5.6 ng/ml was established to increase the risk of recurrence by 2.38-fold (p = 0.002), whereas an LSTg ≥ 0.285 ng/ml increased the risk of relapse by 3.087-fold (p < 0.001).

CONCLUSION

As a result of this study, we determined that the optimum cut-off level for both ASTg and LSTg may be lower than those previously reported. Using such a lower cut-off may improve sensitivity for detecting relapse.

摘要

背景

血清甲状腺球蛋白(Tg)是分化型甲状腺癌(DTC)患者随访中的关键参数。当前指南建议在促甲状腺激素(TSH)水平>30 μU/ml时检测刺激后的Tg,以及在TSH<0.1 μU/ml时检测抑制后的Tg。尽管刺激后的Tg水平<1 ng/ml已显示出良好的预后,但即使Tg水平较低仍可能发生复发。最近,有人提出了极低的刺激后Tg临界值来确定这些患者的复发风险。在本研究中,我们旨在评估一组DTC患者在放射性碘消融治疗(RAI)前获得的消融刺激后Tg(ASTg)与初次治疗后6 - 12个月获得的晚期刺激后Tg(LSTg)之间的关联。我们还旨在确定复发的Tg临界值。

方法

我们回顾性分析了2000年1月至2010年12月在我院诊断为低或中度风险DTC的393例患者,平均随访期为64.4个月(范围14 - 192个月)。本研究中所有刺激后的Tg水平均在左甲状腺素撤药后进行检测。

结果

组织病理学分析显示,362例(92.1%)患者为乳头状癌,31例(7.9%)患者为滤泡状癌。我们的病例中324例(82.4%)为女性,69例(17.6%)为男性。82例(20.9%)患者出现复发。在ASTg≥2 ng/ml和LSTg≥2 ng/ml的患者中,复发明显更常见(p分别为0.004和p<0.001)。在甲状腺球蛋白抗体(Tg-ab)阴性的患者中,ASTg值≥5.6 ng/ml使复发风险增加2.38倍(p = 0.002),而LSTg≥0.285 ng/ml使复发风险增加3.087倍(p<0.001)。

结论

作为本研究的结果,我们确定ASTg和LSTg的最佳临界值可能低于先前报道的值。使用这样较低的临界值可能会提高检测复发的敏感性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验